Literature DB >> 30125418

Perinatal mortality, timing of delivery and prenatal management of monoamniotic twin pregnancy: systematic review and meta-analysis.

F D'Antonio1,2, A Odibo3, V Berghella4, A Khalil5,6, K Hack7, G Saccone8, F Prefumo9, D Buca10, M Liberati10, G Pagani11, G Acharya1,12,13.   

Abstract

OBJECTIVE: To quantify the rate of perinatal mortality in monochorionic monoamniotic (MCMA) twin pregnancies, according to gestational age, and to ascertain the incidence of mortality in pregnancies managed as inpatients compared with those managed as outpatients.
METHODS: MEDLINE, EMBASE and CINAHL databases were searched for studies on monoamniotic twin pregnancy. The primary outcomes explored were the incidence of intrauterine death (IUD), neonatal death (NND) and perinatal death (PND) in MCMA twins at different gestational-age windows (24-30, 31-32, 33-34, 35-36 and ≥ 37 weeks of gestation). The secondary outcomes were the incidence of IUD, NND and PND in MCMA twins according to the type of fetal monitoring (inpatient vs outpatient), and the incidence of delivery ahead of schedule. Random-effects model meta-analyses were used to analyze the data.
RESULTS: Twenty-five studies (1628 non-anomalous twins reaching 24 weeks of gestation) were included. Single and double intrauterine deaths occurred in 2.5% (95% CI, 1.8-3.3%) and 3.8% (95% CI, 2.5-5.3%) of cases, respectively. IUD occurred in 4.3% (95% CI, 2.8-6.2%) of twins at 24-30 weeks, in 1.0% (95% CI, 0.6-1.7%) at 31-32 weeks and in 2.2% (95% CI, 0.9-3.9%) at 33-34 weeks of gestation, while there was no case of IUD, either single or double, from 35 weeks of gestation. In MCMA twin pregnancies managed mainly as inpatients, the incidence of IUD was 3.0% (95% CI, 1.4-5.2%), while the corresponding figure for those managed mainly as outpatients was 7.4% (95% CI, 4.4-11.1%). Finally, 37.8% (95% CI, 28.0-48.2%) of MCMA pregnancies were delivered before the scheduled time, due mainly to spontaneous preterm labor or abnormal cardiotocographic findings.
CONCLUSIONS: MCMA twins are at high risk of perinatal loss during the third trimester of pregnancy, with the large majority of such losses occurring as apparently unexpected events. Inpatient management seems to be associated with a lower rate of mortality, although further studies are needed in order to establish the appropriate type and timing of prenatal assessment in these pregnancies.
Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  monoamniotic twin pregnancy; neonatal outcome; systematic review; timing of delivery

Mesh:

Year:  2019        PMID: 30125418     DOI: 10.1002/uog.20100

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  4 in total

1.  Association between fetal sex and pregnancy outcomes among women with twin pregnancies: a multicenter cross-sectional study.

Authors:  Satoru Funaki; Kohei Ogawa; Nobuaki Ozawa; Satoshi Hosoya; Aikou Okamoto; Kevin Y Urayama; Naho Morisaki; Haruhiko Sago
Journal:  Arch Gynecol Obstet       Date:  2022-05-27       Impact factor: 2.344

2.  Perinatal outcome in monoamniotic twin pregnancies during a 10-year period: a single center, descriptive study.

Authors:  Eleonor Tiblad; Lotta Herling; Ingrid Söderhult
Journal:  Arch Gynecol Obstet       Date:  2022-03-26       Impact factor: 2.344

3.  Mode of birth in monochorionic versus dichorionic twin pregnancies: a retrospective study from a large tertiary centre in Germany.

Authors:  Lena Wandel; Harald Abele; Jan Pauluschke-Fröhlich; Karl Oliver Kagan; Sara Brucker; Katharina Rall
Journal:  BMC Pregnancy Childbirth       Date:  2022-03-17       Impact factor: 3.007

4.  Pregnancy outcomes of dichorionic triamniotic triplet pregnancies after in vitro fertilization-embryo transfer: multifoetal pregnancy reduction versus expectant management.

Authors:  Pei Cai; Yan Ouyang; Fei Gong; Xihong Li
Journal:  BMC Pregnancy Childbirth       Date:  2020-03-17       Impact factor: 3.007

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.